BIB vs. ARKG
Compare and contrast key facts about ProShares Ultra Nasdaq Biotechnology (BIB) and ARK Genomic Revolution Multi-Sector ETF (ARKG).
BIB and ARKG are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. BIB is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (200%). It was launched on Apr 7, 2010. ARKG is an actively managed fund by ARK Investment Management. It was launched on Oct 31, 2014.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BIB or ARKG.
Correlation
The correlation between BIB and ARKG is 0.79, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Performance
BIB vs. ARKG - Performance Comparison
Key characteristics
BIB:
0.01
ARKG:
-0.11
BIB:
0.25
ARKG:
0.12
BIB:
1.03
ARKG:
1.01
BIB:
0.00
ARKG:
-0.06
BIB:
0.02
ARKG:
-0.21
BIB:
12.78%
ARKG:
22.46%
BIB:
35.33%
ARKG:
40.28%
BIB:
-67.24%
ARKG:
-80.10%
BIB:
-49.44%
ARKG:
-73.63%
Returns By Period
In the year-to-date period, BIB achieves a 9.47% return, which is significantly lower than ARKG's 25.16% return. Over the past 10 years, BIB has underperformed ARKG with an annualized return of -3.01%, while ARKG has yielded a comparatively higher 3.14% annualized return.
BIB
9.47%
9.78%
-15.88%
-2.23%
-2.52%
-3.01%
ARKG
25.16%
22.23%
12.22%
-6.15%
-4.27%
3.14%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
BIB vs. ARKG - Expense Ratio Comparison
BIB has a 0.95% expense ratio, which is higher than ARKG's 0.75% expense ratio.
Risk-Adjusted Performance
BIB vs. ARKG — Risk-Adjusted Performance Rank
BIB
ARKG
BIB vs. ARKG - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BIB vs. ARKG - Dividend Comparison
BIB's dividend yield for the trailing twelve months is around 1.54%, while ARKG has not paid dividends to shareholders.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 1.54% | 1.69% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 1.94% | 1.34% |
Drawdowns
BIB vs. ARKG - Drawdown Comparison
The maximum BIB drawdown since its inception was -67.24%, smaller than the maximum ARKG drawdown of -80.10%. Use the drawdown chart below to compare losses from any high point for BIB and ARKG. For additional features, visit the drawdowns tool.
Volatility
BIB vs. ARKG - Volatility Comparison
The current volatility for ProShares Ultra Nasdaq Biotechnology (BIB) is 11.08%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 13.69%. This indicates that BIB experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.